Novo hosted its 2026 Capital Markets Day on Sept. 21, where it disclosed 2030 financial targets, including mid-single-digit top-line growth and roughly steady operating margins. Shares fell 8%.
Novo's Wegovy and Wegovy pill are expanding the obesity treatment market with strong efficacy and convenience, and are poised to remain key drugs until US and EU patent expirations begin in 2031-32.
Tresiba's strong profile in the long-acting insulin market hasn't been enough to defend it from US pricing pressure due to competition from Sanofi and Lilly, and biosimilar insulins have weighed on category pricing since 2017.
|
Metric
|
NOVO B
|
SNY
|
AZN
|
|---|---|---|---|
Price/Earnings (Normalized) | 8.84 | 11.54 | 15.22 |
Price/Book Value | 5.59 | 1.34 | 5.09 |
Price/Sales | 3.47 | 1.73 | 4.25 |
Price/Cash Flow | 8.65 | 7.13 | 16.83 |
|
Metric
|
NOVO B
|
SNY
|
AZN
|
|---|---|---|---|
Quick Ratio | 0.64 | 0.49 | 0.66 |
Current Ratio | 0.87 | 0.99 | 0.89 |
Interest Coverage | — | 8.05 | 7.99 |
|
Metric
|
NOVO B
|
SNY
|
AZN
|
|---|---|---|---|
Return on Assets (Normalized) | 21.31% | 7.96% | 9.00% |
Return on Equity (Normalized) | 59.99% | 14.96% | 21.69% |
Return on Invested Capital (Normalized) | 34.79% | 11.28% | 14.36% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|qNk!zx> | LOCK|W? | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|s$K^?> | LOCK|Dv! | $616B | |||
| AbbVie Inc
ABBV
| LOCK|^s%>#$ | LOCK|j?p | $504B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|nnvtv#J | LOCK|h> | $366B | |||
| Merck & Co Inc
MRK
| LOCK|!>T?R$? | LOCK|f>@ | $360B | |||
| Novartis AG ADR
NVS
| LOCK|F^$H#>z | LOCK|#f | $286B | |||
| AstraZeneca PLC
AZN
| LOCK|Lfg$$>>Y | LOCK|#q! | $256B | |||
| Amgen Inc
AMGN
| LOCK|C^<dK<GG | LOCK|&HY | $234B | |||
| Gilead Sciences Inc
GILD
| LOCK|#cXP%z | LOCK|#W | $194B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|?#!%!>% | LOCK|?@ | $172B |
United States